Core Insights - Aier Eye Hospital has been awarded the "2024-2025 Most Respected Enterprise in New Quality Productivity" for its achievements in digital innovation and quality development [2] - The company operates 974 hospitals and eye centers globally, with 811 located in mainland China, demonstrating extensive coverage of quality eye care resources [2] - Aier Eye Hospital's innovative business model includes a tiered chain system that enhances medical resource allocation and accessibility, especially in underserved areas [3] Business Model Innovation - The tiered chain model consists of flagship hospitals in major cities, provincial hospitals, and county-level hospitals, optimizing the distribution of high-quality eye care services [3] - Aier has also introduced a "cross-subsidy" model to support low-income patients, enhancing the accessibility of eye care services [3] Research and Development - The company emphasizes innovation-driven strategies, establishing a comprehensive ecosystem for research, clinical application, and talent development [4] - Aier has strengthened partnerships with top universities to enhance its research capabilities and improve the quality of eye care [4] Quality and Safety Management - Aier Eye Hospital focuses on a systematic quality control framework and digital transformation to ensure patient safety and service quality [5] - The company aims to synchronize its medical technology and services with international standards, enhancing global patient access to innovative treatments [5] Digital Transformation - Since 2018, Aier has initiated a "Digital Ophthalmology" model, leveraging big data to improve service efficiency and quality [5] - The establishment of a health big data center and the development of smart hospital systems have been key components of this digital strategy [5] Artificial Intelligence Integration - Aier Eye Hospital has developed a comprehensive platform that integrates AI technologies into its service delivery, enhancing diagnostic and treatment processes [6] - The company aims to create a world-class eye medical center by leveraging new quality productivity and optimizing resource allocation [6]

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology sector [5][4]. Core Insights - The pharmaceutical sector has underperformed the overall market, with a significant decline in various sub-sectors, including a 6.88% drop in the biotechnology sector [1][32]. - Hidradenitis Suppurativa (HS) is identified as a chronic, recurrent inflammatory skin disease with a low prevalence in China and the U.S., highlighting the potential market for treatment options [2][10]. - The report emphasizes the increasing market share of new biologics targeting IL-17A and IL-17A/F, which are expected to outperform traditional therapies like Adalimumab [2][18]. Summary by Sections Market Performance - The overall A-share market declined by 4.32%, with the biotechnology sector falling by 6.88%, indicating a weaker performance compared to the broader market [1][32]. - Specific declines were noted in chemical pharmaceuticals (7.02%), biological products (7.46%), and medical services (6.90%) [1][32]. Hidradenitis Suppurativa Treatment Overview - HS affects approximately 0.03% of the population in China, with around 400,000 cases, and has been included in the rare disease directory [2][10]. - First-line treatments primarily involve antibiotics, while second-line therapies include biologics such as Adalimumab and newer agents targeting IL-17A and IL-17A/F [2][10]. Company Earnings Forecast and Investment Ratings - Key companies such as Mindray Medical, WuXi AppTec, and Aier Eye Hospital are rated as "Outperform," with projected net profits for 2024 ranging from 1.4 billion to 116.7 billion CNY [4][42]. - The report highlights the strong growth potential in the CXO sector, particularly in CDMO and clinical CRO services, driven by new orders and emerging business lines [42][43]. Investment Strategy - The report suggests focusing on undervalued stocks in the medical device and pharmacy sectors, which have already priced in various policy risks [42]. - It also emphasizes the importance of monitoring the clinical progress of innovative drugs in overseas markets, as this can significantly impact their commercialization potential [43][42]. Recommended Stocks - Mindray Medical is noted for its strong R&D and sales capabilities, benefiting from domestic healthcare infrastructure development [44]. - WuXi AppTec is recognized for its comprehensive service capabilities across the new drug development chain, poised to benefit from the global outsourcing market [44]. - Aier Eye Hospital is highlighted for its scale and commitment to introducing international standards in eye care [44].

"每一次为患者手术，都是一份信任的托付。突破400例，意味着我们肩上的责任更重一分。"刘云川表示，"真正 的精准医疗，不在于追求最高的手术量，而在于为每一双眼睛找到最理想的手术方案。我们的核心差异在于，始 终坚持以专家的深度思考驾驭前沿技术，将科技的确定性与我们经验的灵活性相结合，为患者铺就一条安心、清 晰的视觉之路。" 日前，国内屈光手术权威专家、济南爱尔眼科（300015）医院刘云川院长主导的新一代蔡司VISUMAX800机器人 全飞秒手术(SMILE pro)成功突破400例。 400例手术，是四百次精准的个性化定制。在刘云川看来，顶尖设备是基石，而专家的"精"与"验"才是实现卓越疗 效的核心。每一台SMILE pro手术的背后，都是她基于深厚理论功底与数十年近视手术临床经验所做的精准判 断：面对不同的角膜条件与用眼需求，刘云川团队在术前进行精细化数据解读，确保手术方案与每位患者的眼部 条件及生活品质追求完美契合。凭借对设备性能的极致理解与炉火纯青的操作，她将"10秒内完成切削"的技术参 数，升华为"稳、准、柔"的患者手术体验，帮助患者获得长期、稳定的视觉健康。 ...

Core Viewpoint - The Shenzhen-Hong Kong Stock Connect Medical Index (983036) closed at 4375.4 points on November 25, with a 0.52% increase and a trading volume of 8.459 billion HKD, indicating a positive market sentiment in the healthcare sector [1]. Group 1: Index Performance - The index had 40 stocks rising and 16 stocks falling on the day, with Ping An Good Doctor leading the gainers at a 4.27% increase, while Ruimaite led the decliners with a 1.98% drop [1]. - The index's turnover rate was 0.84%, reflecting moderate trading activity [1]. Group 2: Component Stocks Details - The top ten component stocks of the index include: - Mindray Medical (14.56% weight, 193.88 HKD, 0.46% increase, market cap 235.068 billion HKD) [1] - Yeye Eye Hospital (11.62% weight, 11.59 HKD, 0.35% increase, market cap 108.081 billion HKD) [1] - Lejin Medical (4.85% weight, 15.80 HKD, 0.45% increase, market cap 29.126 billion HKD) [1] - Aimeike (4.80% weight, 145.54 HKD, -0.31% decrease, market cap 44.039 billion HKD) [1] - Yuyue Medical (4.66% weight, 35.67 HKD, -0.14% decrease, market cap 35.758 billion HKD) [1] - Yingke Medical (3.64% weight, 40.26 HKD, 0.20% increase, market cap 26.362 billion HKD) [1] - Furuishi (3.59% weight, 65.75 HKD, -1.50% decrease, market cap 17.422 billion HKD) [1] - Meinian Health (3.58% weight, 5.42 HKD, 0.74% increase, market cap 21.215 billion HKD) [1] - Sinopharm (3.35% weight, 18.55 HKD, 0.49% increase, market cap 57.888 billion HKD) [1] - Ping An Good Doctor (2.63% weight, 13.33 HKD, 4.27% increase, market cap 28.822 billion HKD) [1]. Group 3: Capital Flow - The net outflow of main funds from the index's component stocks totaled 251 million HKD, while retail investors saw a net inflow of 199 million HKD [1]. - The detailed capital flow indicates that while main funds were withdrawing, retail investors were actively buying into the market [2]. Group 4: Recent Adjustments - In the last 10 days, the index underwent adjustments, adding one new stock, Jianfa Zhixin, which is in the medical biology sector with a market cap of 13.886 billion HKD [3].

Core Viewpoint - The Shenzhen-Hong Kong Medical Index (983035) closed at 4488.12 points on November 25, with a 0.45% increase and a trading volume of 7.719 billion yuan, indicating a stable performance in the healthcare sector [1]. Group 1: Index Performance - On the same day, 40 out of the index's constituent stocks rose, with Ping An Good Doctor leading the gains at 4.27%, while 16 stocks declined, with Ruimaite leading the losses at 1.98% [1]. - The top ten constituent stocks of the Shenzhen-Hong Kong Medical Index include: - Mindray Medical (14.56% weight, market cap 235.068 billion yuan) [1] - Yier Eye Hospital (11.62% weight, market cap 108.081 billion yuan) [1] - Lejin Medical (4.85% weight, market cap 29.126 billion yuan) [1] - Aimeike (4.80% weight, market cap 44.039 billion yuan) [1] - Yuyue Medical (4.66% weight, market cap 35.758 billion yuan) [1] - Yingke Medical (3.64% weight, market cap 26.362 billion yuan) [1] - Furuishi (3.59% weight, market cap 17.422 billion yuan) [1] - Meinian Health (3.58% weight, market cap 21.215 billion yuan) [1] - China National Pharmaceutical (3.35% weight, market cap 57.888 billion yuan) [1] - Ping An Good Doctor (2.63% weight, market cap 28.822 billion yuan) [1]. Group 2: Capital Flow - The net outflow of main funds from the constituent stocks totaled 251 million yuan, while retail investors saw a net inflow of 199 million yuan [3]. - The detailed capital flow for selected stocks includes: - Aimeike: Main net inflow of 23.5405 million yuan, retail net outflow of 35.0461 million yuan [3]. - New Mileage: Main net inflow of 14.1523 million yuan, retail net outflow of 6.6983 million yuan [3]. - Jianfan Biological: Main net inflow of 4.5525 million yuan, retail net outflow of 8.5385 million yuan [3]. - A total of one stock was newly added to the Shenzhen-Hong Kong Medical Index in the last ten days [4].

证券代码：300015 证券简称：爱尔眼科 公告编号：2025-094 爱尔眼科医院集团股份有限公司 关于召开 2025 年第三次临时股东大会的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或 重大遗漏。 爱尔眼科医院集团股份有限公司（以下简称"公司"）于 2025 年 11 月 11 日在中国证 监会指定的信息披露网站巨潮资讯网（www.cninfo.com.cn）发布了《关于召开 2025 年第 三次临时股东大会的通知》，本次股东大会采用现场投票与网络投票相结合的方式召开， 现将有关事项提示如下： 一、召开会议的基本情况 1、股东会届次：2025 年第三次临时股东大会 2、股东会的召集人：董事会 3、本次会议的召集、召开符合《中华人民共和国公司法》《深圳证券交易所创业板股 票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号—创业板上市公司规范运作》 等法律、行政法规、部门规章、规范性文件及《公司章程》的有关规定。 4、会议时间： （1）现场会议时间：2025 年 11 月 27 日 14:30 （2）网络投票时间：通过深圳证券交易所系统进行网络投票的 ...

Core Insights - The establishment of the first "Difficult Lacrimal Disease Diagnosis and Treatment Center" by Aier Eye Hospital Group in Wuhan aims to provide specialized care for complex lacrimal diseases, leveraging multidisciplinary collaboration and precision treatment [1][2] - The center focuses on conditions such as lacrimal duct adhesion, chronic lacrimal duct rupture, and congenital absence of lacrimal ducts, addressing a significant healthcare need in Central China and nationwide [1] - Aier Eye Hospital plans to create a tiered diagnosis and treatment database for lacrimal diseases, standardizing treatment protocols and establishing a comprehensive service loop from diagnosis to rehabilitation [2] Summary by Sections Establishment and Purpose - Aier Eye Hospital Group has inaugurated its first center dedicated to difficult lacrimal diseases in Wuhan, which will serve as a model for future centers across the country [1] - The center aims to provide one-stop diagnostic and treatment services for patients suffering from complex lacrimal conditions [1] Medical Collaboration and Expertise - The center integrates experts from various fields, including lacrimal, nasal, and imaging specialties, to create a systematic multidisciplinary treatment approach [1] - The clinical challenges associated with complex lacrimal diseases often stem from trauma, inflammation, congenital abnormalities, or previous surgical failures, leading to low success rates in conventional surgeries [1] Future Plans and Community Support - Aier Eye Hospital intends to establish additional centers across the country, contributing to a national network for specialized lacrimal disease treatment [2] - The organization is also collaborating with the Eye Care Charity Foundation to provide financial assistance of up to 3,000 yuan for eligible patients, alleviating their economic burden and promoting eye health [2]

11 月 21 日，以 " 智领健康未来 " 为主题的 2025 华夏大健康产业发展暨康复服务大会在北京召开。作为连续四届引领行业风向的标杆盛会，科技与创新 始终是贯穿全程的灵魂主线，而医疗健康企业在环境、社会及治理方面的表现同样被社会各界关注。 万得 ESG高级分析师 受邀发表了主题演讲，详细介绍了蒲公英指数的构建背景、评估体系及市场表现，强调该指数为医疗健康行业可持续发展提供了重 要参考。 万得首先介绍了 Wind 万得的业务背景： "Wind 是一家专业化的信息服务机构，为金融领域开发了信息检索、数据提取及组合管理等专业工具，是国内外 机构投资者的重要合作伙伴。 " 她特别指出， Wind 构建的独立 ESG 评级体系已广泛应用于政策研究、金融决策和企业实践当中，例如国务院发展研究 中心发布的报告及可持续挂钩债券发行实践。 蒲公英指数亦是 Wind ESG 评级体系的一次创新性应用。该指数由华夏时报大健康研究院与万得联合研发，从医疗健康领域 A 股 495 家公司中精选前 50 家组成 " 蒲公英 50 指数 " ，港股 262 家公司中精选 30 家组成 " 蒲公英 30 指数 " ，每月根据 ESG ...

Core Insights - The International Retina Summit 100 (IRS100·2025) was held in Changsha, China, focusing on the theme "Focusing on Clinical, Integrating Innovation, Building Brightness Together" [1][2] - The event featured over 300 ophthalmology experts discussing cutting-edge technologies and solutions for retinal diseases, emphasizing global collaboration and innovation in the field [2][4] Group 1: Event Overview - IRS100·2025 included various forums covering topics such as gene therapy, artificial intelligence, surgical robotics, and stem cell research, showcasing the latest advancements in retinal medicine [1][2] - The summit aimed to enhance academic exchanges and promote the efficient translation of scientific achievements into clinical applications [4][6] Group 2: Key Contributions and Research - Notable experts presented significant research findings, including the identification of new pathogenic genes for familial exudative vitreoretinopathy (FEVR) and advancements in the treatment of retinoblastoma [10][12] - The summit highlighted the importance of early intervention in diabetic retinopathy and the potential of innovative treatment methods to improve patient outcomes [16][17] Group 3: Future Directions - The event underscored the need for international cooperation and foundational research breakthroughs to elevate the standard of care for retinal diseases [8][19] - The commitment to integrating AI, gene therapy, and robotic surgery into clinical practice was emphasized as a strategy to enhance personalized and precise solutions for complex retinal conditions [19][20]

Core Viewpoint - The importance of listed companies in stabilizing the capital market and promoting sustainable development is increasingly recognized, especially in the current environment where market sentiment is volatile. High-quality companies that focus on core operations and deliver excellent performance are essential to restore investor confidence and stabilize market expectations [1]. Group 1: Market Valuation and Investment Opportunities - A-share valuations are currently at a low level, indicating potential for recovery and highlighting long-term investment value [2][3]. - The medical industry is expected to grow significantly due to China's large population and increasing healthcare demands, driven by the "Healthy China" strategy [2]. - The market is experiencing a divergence where funds are increasingly concentrated on high-quality companies, reflecting a shift towards value investing [4][5]. Group 2: Company Actions and Strategies - Companies like Aier Eye Hospital are committed to aligning interests with investors and enhancing performance, achieving a market value of approximately 80 billion yuan, which is 12 times its initial listing value [6]. - Dabeinong is balancing short-term and long-term goals through employee stock ownership plans to ensure sustainable growth [6]. - Guolinda aims for stable revenue growth and successful cloud transformation while focusing on shareholder returns [7]. Group 3: Economic Environment and Future Outlook - Positive fiscal policies are anticipated in the second half of the year, which may improve the macroeconomic environment and boost investor confidence [3]. - The A-share market is expected to gradually return to value investing as macro policies adjust and market sentiment stabilizes [2][3]. - The inclusion of A-shares in the MSCI index is seen as a beneficial factor, indicating a potential shift in market investment styles towards high-quality growth companies [4].